“…Other specified indications included rapid growth, potentially life-threatening complications, segmental distribution, psychosocial stress, failure of systemic corticosteroids, and avoidance of aggressive and potentially scarring procedures. Two-thirds of the studies included IHs in multiple anatomic sites, whereas one-third focused on IHs in specific locations, such as periorbital (6)(7)(8)(9)(10)(11)(12), airway (13), parotid (14), face (15,16), and head and neck (17,18).…”
To systematically review the literature evaluating efficacy and adverse events of propranolol treatment for infantile hemangiomas, we searched the MEDLINE and Cochrane databases for all studies examining the response of infantile hemangiomas (IHs) to propranolol published between June 12, 2008, and June 15, 2012. Forty-one studies with 1,264 patients were included; 74% of patients were female and approximately 30% had received other treatments before propranolol. Propranolol was initiated at a mean age of 6.6 months at a mean dose of 2.1 mg/kg/day and for a mean treatment duration of 6.4 months. The response rate for patients with IHs treated with propranolol was 98% (range 82%-100%), with response rate defined as any improvement with propranolol. Treatment response rates were comparable for studies evaluating IHs at specific sites, such as periorbital IHs. Studies that followed patients after treatment completion reported IH rebound growth in 17% of patients. There were 371 adverse events reported in 1,189 patients. The most common adverse events were changes in sleep (n = 136) and acrocyanosis (n = 61). Serious adverse events were rare, with reports of symptomatic hypotension in five patients, hypoglycemia in four, and symptomatic bradycardia in one. This systematic review of 1,264 patients treated with propranolol for IHs showed a high rate of efficacy and a low rate of serious adverse events.
“…Other specified indications included rapid growth, potentially life-threatening complications, segmental distribution, psychosocial stress, failure of systemic corticosteroids, and avoidance of aggressive and potentially scarring procedures. Two-thirds of the studies included IHs in multiple anatomic sites, whereas one-third focused on IHs in specific locations, such as periorbital (6)(7)(8)(9)(10)(11)(12), airway (13), parotid (14), face (15,16), and head and neck (17,18).…”
To systematically review the literature evaluating efficacy and adverse events of propranolol treatment for infantile hemangiomas, we searched the MEDLINE and Cochrane databases for all studies examining the response of infantile hemangiomas (IHs) to propranolol published between June 12, 2008, and June 15, 2012. Forty-one studies with 1,264 patients were included; 74% of patients were female and approximately 30% had received other treatments before propranolol. Propranolol was initiated at a mean age of 6.6 months at a mean dose of 2.1 mg/kg/day and for a mean treatment duration of 6.4 months. The response rate for patients with IHs treated with propranolol was 98% (range 82%-100%), with response rate defined as any improvement with propranolol. Treatment response rates were comparable for studies evaluating IHs at specific sites, such as periorbital IHs. Studies that followed patients after treatment completion reported IH rebound growth in 17% of patients. There were 371 adverse events reported in 1,189 patients. The most common adverse events were changes in sleep (n = 136) and acrocyanosis (n = 61). Serious adverse events were rare, with reports of symptomatic hypotension in five patients, hypoglycemia in four, and symptomatic bradycardia in one. This systematic review of 1,264 patients treated with propranolol for IHs showed a high rate of efficacy and a low rate of serious adverse events.
“…Several cases in the literature report successful treatment of periocular infantile hemangiomas . However, there are only a few reports on the treatment of episcleral hemangiomas .…”
Episcleral hemangiomas are usually associated with neonatal hemangiomatosis. Recently, propranolol has been described for the treatment of this entity. We present for the first time a patient with an episcleral hemangioma without neonatal hemangiomatosis successfully treated with topical timolol.
“…7,[34][35][36] Visible changes between the 1 st and the 3 rd day of therapy are explained with vasospasms following the reduction of nitric oxide release. 4 In the study group, a change of color or reduction of tension in the 1 st week of treatment was observed in 70% of patients, while at the end of the 1 st month it was noted in over 90% of children.…”
Section: Resultsmentioning
confidence: 99%
“…The treatment should last 6-8 months, but may be extended to 1-2 years. 7,8,34,35 The treatment should be continued until the end of the proliferative phase, to a minimum of 1 year of age, and in periocular hemangiomas until the defect (astigmatism) is corrected. 35,37,38 Too early or rapid withdrawal may result in recurrence.…”
Background. Propranolol has become the treatment of choice for infantile hemangiomas (IH). Neither the pathogenesis of IH nor the mechanism of action of propranolol on them are well understood. Possible explanations include the inhibition of angiogenesis by decreasing vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), induction of vascular endothelial cell apoptosis and vasoconstriction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.